IIM
MCID: MYS005
MIFTS: 62

Myositis (IIM)

Categories: Genetic diseases, Infectious diseases, Muscle diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Myositis

MalaCards integrated aliases for Myositis:

Name: Myositis 58 12 77 30 56 6 44 45 15 17 74
Myopathy, Familial Idiopathic Inflammatory; Iim 58
Myopathy, Familial Idiopathic Inflammatory 58
Inflammatory Disorder of Muscle 12
Iim 58

Characteristics:

OMIM:

58
Inheritance:
autosomal dominant


HPO:

33
myositis:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:633
OMIM 58 160750
MeSH 45 D009220
NCIt 51 C27578
SNOMED-CT 69 26889001
MedGen 43 C0027121
SNOMED-CT via HPO 70 128496001 249939004 263681008
UMLS 74 C0027121

Summaries for Myositis

MedlinePlus : 44 Myositis means inflammation of the muscles that you use to move your body. An injury, infection, or autoimmune disease can cause it. Two specific kinds are polymyositis and dermatomyositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash. Other symptoms of myositis may include Fatigue after walking or standing Tripping or falling Trouble swallowing or breathing Doctors may use a physical exam, lab tests, imaging tests and a muscle biopsy to diagnose myositis. There is no cure for these diseases, but you can treat the symptoms. Polymyositis and dermatomyositis are first treated with high doses of a corticosteroid. Other options include medications, physical therapy, exercise, heat therapy, assistive devices, and rest. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary : Myositis, also known as myopathy, familial idiopathic inflammatory; iim, is related to inclusion body myositis and granulomatous myositis, and has symptoms including muscle weakness, myoclonus and back pain. An important gene associated with Myositis is CAPN3 (Calpain 3), and among its related pathways/superpathways is tRNA Aminoacylation. The drugs Simvastatin and tannic acid have been mentioned in the context of this disorder. Affiliated tissues include lung, skeletal muscle and bone, and related phenotypes are proximal muscle weakness and myositis

Disease Ontology : 12 A myopathy characterized by muscle inflammation.

Wikipedia : 77 Myositis is inflammation or swelling of the muscles. Injury, medicines, infection, or an immune disorder... more...

Description from OMIM: 160750

Related Diseases for Myositis

Diseases in the Myositis family:

Bacterial Myositis Viral Myositis

Diseases related to Myositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 482)
# Related Disease Score Top Affiliating Genes
1 inclusion body myositis 34.3 APP GNE MSTN
2 granulomatous myositis 33.7 PIK3C2A TTN
3 myositis fibrosa 33.6 MB PIK3C2A
4 antisynthetase syndrome 32.5 HARS TARS
5 myopathy 32.2 CAPN3 DYSF GNE TTN
6 metabolic encephalomyopathic crises, recurrent, with rhabdomyolysis, cardiac arrhythmias, and neurodegeneration 30.4 CHKB MB PIK3C2A
7 compartment syndrome 30.4 CHKB MB PIK3C2A
8 polyglucosan body myopathy 1 with or without immunodeficiency 30.3 CAPN3 DMD
9 proliferative fasciitis 30.3 MB SERPINA3
10 muscular dystrophy, becker type 30.0 DMD DYSF PIK3C2A
11 limb-girdle muscular dystrophy 30.0 CAPN3 DMD DYSF TTN
12 anterior compartment syndrome 29.9 DYSF PIK3C2A
13 gas gangrene 29.9 DMD MB PIK3C2A
14 muscular dystrophy-dystroglycanopathy , type c, 5 29.9 CAPN3 DYSF TTN
15 localized lipodystrophy 29.9 DMD DYSF
16 muscular dystrophy 29.6 TTN PIK3C2A MSTN GNE DYSF DMD
17 neuromuscular disease 29.4 DMD GNE TTN
18 miyoshi muscular dystrophy 29.4 TTN GNE DYSF DMD CAPN3
19 congenital disorder of glycosylation, type iim 12.6
20 myositis ossificans 12.5
21 focal myositis 12.4
22 fibrodysplasia ossificans progressiva 12.3
23 viral myositis 12.3
24 bacterial myositis 12.3
25 infective myositis 12.3
26 fungal myositis 12.3
27 idiopathic eosinophilic myositis 12.2
28 overlap myositis 12.2
29 pyomyositis 12.1
30 juvenile overlap myositis 12.1
31 idiopathic inflammatory myopathy 12.1
32 slc35a2-congenital disorder of glycosylation 11.9
33 dermatomyositis 11.9
34 orbital plasma cell granuloma 11.6
35 necrotizing autoimmune myopathy 11.4
36 polymyositis 11.4
37 muscle disorders 11.4
38 childhood type dermatomyositis 11.4
39 welander distal myopathy, swedish type 11.3
40 foot drop 11.3
41 proteasome-associated autoinflammatory syndrome 3 11.2
42 juvenile polymyositis 11.1
43 xanthinuria, type ii 11.0
44 osseous heteroplasia, progressive 11.0
45 epidemic pleurodynia 11.0
46 macrophagic myofasciitis 10.6
47 autosomal recessive limb-girdle muscular dystrophy type 2j 10.4 CAPN3 TTN
48 arthritis 10.4
49 autosomal recessive limb-girdle muscular dystrophy type 2f 10.4 CAPN3 DYSF
50 autosomal recessive limb-girdle muscular dystrophy type 2g 10.4 CAPN3 DYSF

Graphical network of the top 20 diseases related to Myositis:



Diseases related to Myositis

Symptoms & Phenotypes for Myositis

Human phenotypes related to Myositis:

33
# Description HPO Frequency HPO Source Accession
1 proximal muscle weakness 33 HP:0003701
2 myositis 33 HP:0100614

Symptoms via clinical synopsis from OMIM:

58
Muscle:
proximal muscle weakness
myositis

Clinical features from OMIM:

160750

UMLS symptoms related to Myositis:


muscle weakness, myoclonus, back pain, myalgia, torticollis, sciatica, muscle cramp, muscle rigidity, muscle spasticity

GenomeRNAi Phenotypes related to Myositis according to GeneCards Suite gene sharing:

27 (show all 13)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.09 PIK3C2A
2 Decreased viability GR00221-A-1 10.09 CHKB GNE PIK3C2A
3 Decreased viability GR00221-A-2 10.09 CHKB PIK3C2A TTN
4 Decreased viability GR00221-A-3 10.09 CHKB GNE
5 Decreased viability GR00221-A-4 10.09 CHKB DYSF GNE PIK3C2A TTN
6 Decreased viability GR00240-S-1 10.09 PIK3C2A
7 Decreased viability GR00301-A 10.09 CHKB DYSF
8 Decreased viability GR00342-S-1 10.09 PIK3C2A TTN
9 Decreased viability GR00342-S-2 10.09 PIK3C2A
10 Decreased viability GR00342-S-3 10.09 PIK3C2A TTN
11 Decreased viability GR00402-S-2 10.09 CHKB DYSF GNE PIK3C2A TTN
12 no effect GR00402-S-1 9.92 AARS APP BACE2 CAPN3 CHKB DMD
13 Decreased hepcidin::fluc mRNA expression GR00253-A 9.76 AARS APP DMD DYSF MSTN NARS

MGI Mouse Phenotypes related to Myositis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.81 AARS APP CAPN3 DMD GNE MB
2 growth/size/body region MP:0005378 9.7 AARS APP BACE2 CAPN3 DMD GNE
3 muscle MP:0005369 9.32 AARS APP CAPN3 CHKB DMD DYSF

Drugs & Therapeutics for Myositis

Drugs for Myositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 227)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 2,Phase 3,Not Applicable 79902-63-9 54454
2
tannic acid Approved Phase 4,Phase 2,Phase 3,Not Applicable 1401-55-4
3
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
4
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 94-09-7, 1994-09-7 2337
5
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
6
Pirfenidone Approved, Investigational Phase 4,Phase 3 53179-13-8 40632
7
Abatacept Approved Phase 4,Phase 3,Phase 2 332348-12-6 10237
8
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
9
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 130881 158781
10
Adenosine Approved, Investigational Phase 4 58-61-7 60961
11
Atorvastatin Approved Phase 4,Not Applicable 134523-00-5 60823
12
Liraglutide Approved Phase 4 204656-20-2 44147092
13
Pentoxifylline Approved, Investigational Phase 4 6493-05-6 4740
14
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable 7440-70-2 271
15
Coenzyme Q10 Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3 303-98-0 5281915
16
Serine Approved, Nutraceutical Phase 4 56-45-1 5951
17
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
18 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
19 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
20 Hypolipidemic Agents Phase 4,Phase 2,Phase 3,Not Applicable
21 Rosuvastatin Calcium Phase 4,Not Applicable 147098-20-2
22 Anticholesteremic Agents Phase 4,Phase 2,Phase 3,Not Applicable
23 Calcium, Dietary Phase 4,Phase 3,Phase 2,Early Phase 1,Not Applicable
24 Lipid Regulating Agents Phase 4,Phase 2,Phase 3,Not Applicable
25 Anti-HIV Agents Phase 4,Not Applicable
26 Anti-Retroviral Agents Phase 4,Not Applicable
27 Reverse Transcriptase Inhibitors Phase 4,Not Applicable
28 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
29 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
30 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
31 Ubiquinone Phase 4,Phase 2,Phase 3
32 Nutrients Phase 4,Phase 2,Phase 3,Not Applicable
33 Vitamins Phase 4,Phase 2,Phase 3,Not Applicable
34 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
35 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
36 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
37 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
38 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
39 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
40 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
41 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
42 Vaccines Phase 4,Phase 3,Not Applicable
43 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
44 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable
45 Adrenocorticotropic Hormone Phase 4,Phase 2
46 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Melanocyte-Stimulating Hormones Phase 4,Phase 2
48 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 beta-endorphin Phase 4,Phase 2
50 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 213)
# Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
3 Living With Statins - Interventional Exercise Study Unknown status NCT02796378 Phase 4 Training+Simvastatin+Q10-placebo;Training+Simvastatin-placebo+Q10-placebo;Training+Simvastatin+Q10
4 Pirfenidone in Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis Unknown status NCT02821689 Phase 4 Pirfenidone
5 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
6 Living With Statins - The Impact of Cholesterol Lowering Drugs on Health, Lifestyle and Well-being Completed NCT02255682 Phase 4 Simvastatin
7 Angiotensin II Blockade and Inflammation in Obesity Completed NCT01684748 Phase 4 Olmesartan medoxomil
8 Stop Atherosclerosis in Native Diabetics Study Completed NCT00147251 Phase 4 FDA approved drugs to treat blood pressure and cholesterol
9 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
10 Abatacept in Juvenile Dermatomyositis Recruiting NCT02594735 Phase 4 Abatacept
11 Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis Recruiting NCT02245841 Phase 4 H.P. Acthar Gel
12 The Effect of Liraglutide on Dietary Lipid Induced Insulin Resistance in Humans Active, not recruiting NCT02403284 Phase 4 Liraglutide;Sugar Pill
13 Pentoxifylline in Lupus Nephritis Not yet recruiting NCT03859570 Phase 4 Pentoxifylline;Placebos
14 Is Myopathy Part of Statin Therapy (IMPOSTER-16) Terminated NCT00127335 Phase 4 cellulose placebo vs. atorvastatin
15 Five-year Actively Controlled Clinical Trial in New Onset Juvenile Dermatomyositis Unknown status NCT00323960 Phase 3 3 MPDN pulse + PDN;3 MPDN pulse + PDN + CSA;3 MPDN pulse + PDN + MTX
16 Arimoclomol in Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3 Arimoclomol
17 An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 Completed NCT02573467 Phase 3 Bimagrumab;Placebo
18 Treatment With TNF Blockade, Infliximab, in Patients With Myositis Completed NCT00443222 Phase 2, Phase 3 Infliximab
19 Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3 BYM338 (Bimagrumab)
20 Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients Completed NCT01925209 Phase 2, Phase 3 BYM338/bimagrumab;Placebo
21 Anakinra in Myositis Completed NCT01165008 Phase 2, Phase 3 Anakinra
22 Rapamycine vs Placebo for the Treatment of Inclusion Body Myositis Completed NCT02481453 Phase 2, Phase 3 Rapamycin;Placebo
23 Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus Completed NCT00504348 Phase 2, Phase 3 Tacrolimus
24 Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM Completed NCT00651040 Phase 3 Prednisone;Methotrexate
25 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
26 High Dose Cyclophosphamide for Treatment of Scleroderma Completed NCT00501995 Phase 3 IV Cyclophosphamide
27 Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients Completed NCT00975000 Phase 3 Cinacalcet;Placebo
28 Scleroderma: Cyclophosphamide or Transplantation (SCOT) Completed NCT00114530 Phase 2, Phase 3 cyclophosphamide
29 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
30 A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection Completed NCT01527110 Phase 3 Intravenous (IV) zanamivir
31 A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children Completed NCT01218308 Phase 3
32 Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) Completed NCT00335985 Phase 3 GB-0998;Placebo of GB-0998
33 Prevention of Glucocorticoid-Induced Osteoporosis in Rheumatic Diseases: Alendronate Versus Alfacalcidol. Completed NCT00138983 Phase 3 Alendronate versus alfacalcidol (1-alpha OH vitamin D)
34 L-Citrulline in Patients With Post-Polio Syndrome Completed NCT02801071 Phase 3 15g L-citrulline daily p.o.;Placebo
35 Belimumab in Idiopathic Inflammatory Myositis Recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
36 Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
37 Rituximab Versus Cyclophosphamide in Connective Tissue Disease-ILD Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
38 Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis Recruiting NCT03813160 Phase 3 Lenabasum 20 mg;Lenabasum 5 mg;Placebo
39 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms Recruiting NCT03653364 Phase 3 Baloxavir Marboxil
40 Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms Recruiting NCT03629184 Phase 3 Baloxavir Marboxil;Oseltamivir
41 Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) Recruiting NCT03486873 Phase 3 Standard of Care (SOC)
42 Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD) Recruiting NCT03857854 Phase 3 Pirfenidone;Placebos
43 A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications Recruiting NCT03381196 Phase 3 Pimodivir 600 mg;Placebo
44 A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection Recruiting NCT03376321 Phase 3 Pimodivir 600 mg;Placebo
45 Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) Active, not recruiting NCT02728752 Phase 3 Octagam 10%
46 An Efficacy and Safety Study of Palovarotene for the Treatment of FOP Active, not recruiting NCT03312634 Phase 3 Palovarotene
47 Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease Not yet recruiting NCT03770663 Phase 3 Cyclophosphamide and azathioprine;Tacrolimus
48 Cycled Testosterone Administration During Pulmonary Rehabilitation in COPD Patients Not yet recruiting NCT03674320 Phase 2, Phase 3 Testosterone Enanthate;Placebo
49 Statins And Cirrhosis: Reducing Events of Decompensation Not yet recruiting NCT03654053 Phase 3 Placebo Oral Tablet;Simvastatin 40mg
50 Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis Terminated NCT03686969 Phase 3 Octanorm

Search NIH Clinical Center for Myositis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cochrane evidence based reviews: myositis

Genetic Tests for Myositis

Genetic tests related to Myositis:

# Genetic test Affiliating Genes
1 Myositis 30

Anatomical Context for Myositis

MalaCards organs/tissues related to Myositis:

42
Lung, Skeletal Muscle, Bone, Testes, T Cells, Skin, Tongue

Publications for Myositis

Articles related to Myositis:

(show top 50) (show all 3440)
# Title Authors Year
1
A Patient with Sjogren's Syndrome and Subsequent Diagnosis of Inclusion Body Myositis and Light-Chain Amyloidosis. ( 30887439 )
2019
2
Myositis ossificans mimicking metaplastic breast cancer on core needle biopsy. ( 30641089 )
2019
3
Severe Influenza A(H1N1) Virus Infection Complicated by Myositis, Refractory Rhabdomyolysis, and Compartment Syndrome. ( 30838046 )
2019
4
Clinical value of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography for interstitial lung disease and myositis in patients with dermatomyositis. ( 30614031 )
2019
5
Fitness genes of group A streptococci in necrotizing fasciitis and myositis. ( 30667379 )
2019
6
Focal Myositis of the Leg Presenting as Fever of Unknown Origin Detected by FDG PET/CT. ( 30562199 )
2019
7
Focal myositis and contracture secondary to amiodarone extravasation from a peripheral cannula. ( 30661048 )
2019
8
Increased risk of coronary heart disease among patients with idiopathic inflammatory myositis: a nationwide population study in Taiwan. ( 30903193 )
2019
9
Relationship between clinical course of nivolumab-related myositis and immune status in a patient with Hodgkin's lymphoma after allogeneic hematopoietic stem cell transplantation. ( 30604316 )
2019
10
Myopathies featuring non-caseating granulomas: Sarcoidosis, inclusion body myositis and an unfolding overlap. ( 30578101 )
2019
11
Sporadic Inclusion Body Myositis: An Acquired Mitochondrial Disease with Extras. ( 30621041 )
2019
12
Assessing the accuracy of neuromuscular ultrasound for inclusion body myositis. ( 30635914 )
2019
13
Resistance Exercise Improves Mitochondrial Quality Control in a Rat Model of Sporadic Inclusion Body Myositis. ( 30641518 )
2019
14
Association between TDP-43 and mitochondria in inclusion body myositis. ( 30742062 )
2019
15
[18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. ( 30760470 )
2019
16
CD8 + T-bet+ cells as a predominant biomarker for inclusion body myositis. ( 30825520 )
2019
17
Inclusion body myositis: clinical features and pathogenesis. ( 30837708 )
2019
18
Mitochondrial DNA depletion in sporadic inclusion body myositis. ( 30850168 )
2019
19
Treatment of idiopathic inflammatory myositis associated interstitial lung disease: A systematic review and meta-analysis. ( 30572131 )
2019
20
Usefulness of serum Krebs von den Lungen-6 for the management of myositis-associated interstitial lung disease. ( 30624752 )
2019
21
Screening for Myositis Antibodies in Idiopathic Interstitial Lung Disease. ( 30838434 )
2019
22
Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma. ( 30855529 )
2019
23
Concomitant myasthenia gravis, myositis, myocarditis and polyneuropathy, induced by immune-checkpoint inhibitors: A life-threatening continuum of neuromuscular and cardiac toxicity. ( 30533536 )
2019
24
Review: Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. ( 30639649 )
2019
25
Acute Proximal Myopathy in a Young Male-A Case of Infectious Myositis. ( 30658484 )
2019
26
Careful Clinical Surveillance Is Important for the Identification of Parechovirus Type A3-Associated Myalgia/Myositis: a Sporadic Case Found in a Season with a Low Level of Its Activity in Yamagata, Japan in 2017. ( 30504645 )
2019
27
Immunoglobulin (Ig)G-4 related myositis - A new entity? ( 30578098 )
2019
28
Detection and phylogenetic analysis of parrot bornavirus 4 identified from a Swedish Blue-winged macaw (Primolius maracana) with unusual nonsuppurative myositis. ( 30598738 )
2019
29
Prevalence of the E321G MYH1 variant for immune-mediated myositis and nonexertional rhabdomyolysis in performance subgroups of American Quarter Horses. ( 30623495 )
2019
30
Serum-soluble TRAIL: a potential biomarker for disease activity in myositis patients. ( 30645753 )
2019
31
Atypical Cardiac Manifestations of Systemic Myositis. ( 30664542 )
2019
32
Poststreptococcal Myalgia and Myositis. ( 30665234 )
2019
33
Gene fitness landscape of group A streptococcus during necrotizing myositis. ( 30667377 )
2019
34
Myositis following hidden intraorbital plant foreign body: A case report. ( 30683531 )
2019
35
Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis. ( 30684913 )
2019
36
Strategy for Suspected Myositis. ( 30711692 )
2019
37
Responsiveness to Change of 5-point MRC scale, Endurance and Functional Evaluation for Assessing Myositis in Daily Clinical Practice. ( 30714969 )
2019
38
Outcomes of Pregnancy in Women With Inflammatory Myositis: A Retrospective Cohort From India. ( 30720702 )
2019
39
Yoga-Induced Myositis Ossificans Traumatica of the Scapholunate Ligament. ( 30723608 )
2019
40
Combining immunofluorescence with immunoblot assay improves the specificity of autoantibody testing for myositis. ( 30726990 )
2019
41
Cancer-associated myositis: an elusive entity. ( 30788076 )
2019
42
Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review. ( 30790071 )
2019
43
Drug-induced paraspinal myositis mimicking acute bilateral sciatica. ( 30796068 )
2019
44
Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies. ( 30824556 )
2019
45
Two cases of myositis ossificans in children, after prolonged immobilization. ( 30839310 )
2019
46
Evaluating the diagnostic utility of new line immunoassays for myositis antibodies in clinical practice: a retrospective study. ( 30840145 )
2019
47
Myositis autoantigen expression correlates with muscle regeneration but not autoantibody specificity. ( 30861336 )
2019
48
The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies. ( 30863950 )
2019
49
A rare presentation of benign acute childhood myositis. ( 30899472 )
2019
50
Myositis associated with Salmonella paratyphi A bacteremia appears to be common. ( 30911492 )
2019

Variations for Myositis

ClinVar genetic disease variations for Myositis:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 FAM111B NM_198947.4(FAM111B): c.1462del (p.Cys488Valfs) deletion Likely pathogenic GRCh37 Chromosome 11, 58893032: 58893032
2 FAM111B NM_198947.4(FAM111B): c.1462del (p.Cys488Valfs) deletion Likely pathogenic GRCh38 Chromosome 11, 59125559: 59125559

Expression for Myositis

Search GEO for disease gene expression data for Myositis.

Pathways for Myositis

Pathways related to Myositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.17 AARS HARS NARS TARS

GO Terms for Myositis

Cellular components related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 9.8 AARS APP CAPN3 CHKB DMD GNE
2 Z disc GO:0030018 9.43 CAPN3 DMD TTN
3 extracellular exosome GO:0070062 9.4 AARS APP DYSF FBL ICOSLG MB
4 astrocyte projection GO:0097449 9.16 APP DMD

Biological processes related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 translation GO:0006412 9.73 AARS HARS NARS TARS
2 platelet degranulation GO:0002576 9.63 APP SERPINA3 TTN
3 muscle organ development GO:0007517 9.58 CAPN3 DMD MSTN
4 response to muscle activity GO:0014850 9.48 CAPN3 MSTN
5 tRNA aminoacylation GO:0043039 9.37 AARS TARS
6 skeletal muscle tissue regeneration GO:0043403 9.33 DMD DYSF MSTN
7 muscle fiber development GO:0048747 9.32 DMD DYSF
8 astrocyte activation GO:0048143 9.26 APP BACE2
9 muscle cell cellular homeostasis GO:0046716 9.13 CAPN3 DMD MSTN
10 tRNA aminoacylation for protein translation GO:0006418 8.92 AARS HARS NARS TARS

Molecular functions related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.8 APP HARS ICOSLG IFIH1 MSTN TTN
2 ATP binding GO:0005524 9.61 AARS CHKB GNE HARS IFIH1 NARS
3 ligase activity GO:0016874 9.46 AARS HARS NARS TARS
4 structural constituent of muscle GO:0008307 9.43 CAPN3 DMD TTN
5 aminoacyl-tRNA ligase activity GO:0004812 8.92 AARS HARS NARS TARS

Sources for Myositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....